{"id":5073,"date":"2023-05-23T09:53:14","date_gmt":"2023-05-23T07:53:14","guid":{"rendered":"https:\/\/www.abiogen.it\/abiogen-pharma-completes-the-acquisition-of-effrx\/"},"modified":"2023-10-17T08:50:37","modified_gmt":"2023-10-17T06:50:37","slug":"acquisition-of-effrx","status":"publish","type":"post","link":"https:\/\/www.abiogen.it\/en\/acquisition-of-effrx\/","title":{"rendered":"Abiogen Pharma completes the acquisition of Effrx"},"content":{"rendered":"<p>PISA, Italy, 29 May 2023 &#8212; Abiogen Pharma S.p.A., Italian leading company in the field of osteoarticular and bone metabolism diseases, is pleased to announce the acquisition of a 97,09% stake in EffRx Pharmaceuticals SA, a Swiss company that develops and markets prescription drugs targeted in particular to musculoskeletal and rare pathologies on European and international markets.<br \/>\nThe key active agent developed by EffRx is buffered soluble alendronate which belongs to a class of non-hormonal pharmaceuticals known as bisphosphonates. This medication has been distributed in Italy by Abiogen Pharma since 2014 under a licence agreement. This deal, completed just a few months after the acquisition of the German company Altamedics at the end of 2022, is intended to consolidate the internationalization strategy that started back in 2015 and is a further step towards achieving an ambitious goal.<\/p>\n<p><a href=\"https:\/\/www.abiogen.it\/wp-content\/uploads\/2023\/10\/Press_Release_Abiogen_EffRx.pdf\" target=\"_blank\" rel=\"noopener\">READ MORE<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PISA, Italy, 29 May 2023 &#8212; Abiogen Pharma S.p.A., Italian leading company in the field of osteoarticular and bone metabolism diseases, is pleased to announce the acquisition of a 97,09% stake in EffRx Pharmaceuticals SA, a Swiss company that develops and markets prescription drugs targeted in particular to musculoskeletal and rare pathologies on European and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4641,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5073","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-non-categorizzato"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Abiogen Pharma completes the acquisition of Effrx - Abiogen<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.abiogen.it\/en\/acquisition-of-effrx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abiogen Pharma completes the acquisition of Effrx - Abiogen\" \/>\n<meta property=\"og:description\" content=\"PISA, Italy, 29 May 2023 &#8212; Abiogen Pharma S.p.A., Italian leading company in the field of osteoarticular and bone metabolism diseases, is pleased to announce the acquisition of a 97,09% stake in EffRx Pharmaceuticals SA, a Swiss company that develops and markets prescription drugs targeted in particular to musculoskeletal and rare pathologies on European and...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.abiogen.it\/en\/acquisition-of-effrx\/\" \/>\n<meta property=\"og:site_name\" content=\"Abiogen\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-23T07:53:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-17T06:50:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.abiogen.it\/wp-content\/uploads\/2023\/05\/acquisizione-effrx-min-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"abnchief\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"abnchief\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abiogen Pharma completes the acquisition of Effrx - Abiogen","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.abiogen.it\/en\/acquisition-of-effrx\/","og_locale":"en_US","og_type":"article","og_title":"Abiogen Pharma completes the acquisition of Effrx - Abiogen","og_description":"PISA, Italy, 29 May 2023 &#8212; Abiogen Pharma S.p.A., Italian leading company in the field of osteoarticular and bone metabolism diseases, is pleased to announce the acquisition of a 97,09% stake in EffRx Pharmaceuticals SA, a Swiss company that develops and markets prescription drugs targeted in particular to musculoskeletal and rare pathologies on European and...","og_url":"https:\/\/www.abiogen.it\/en\/acquisition-of-effrx\/","og_site_name":"Abiogen","article_published_time":"2023-05-23T07:53:14+00:00","article_modified_time":"2023-10-17T06:50:37+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/www.abiogen.it\/wp-content\/uploads\/2023\/05\/acquisizione-effrx-min-1.jpg","type":"image\/jpeg"}],"author":"abnchief","twitter_card":"summary_large_image","twitter_misc":{"Written by":"abnchief","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.abiogen.it\/en\/acquisition-of-effrx\/","url":"https:\/\/www.abiogen.it\/en\/acquisition-of-effrx\/","name":"Abiogen Pharma completes the acquisition of Effrx - Abiogen","isPartOf":{"@id":"https:\/\/www.abiogen.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.abiogen.it\/en\/acquisition-of-effrx\/#primaryimage"},"image":{"@id":"https:\/\/www.abiogen.it\/en\/acquisition-of-effrx\/#primaryimage"},"thumbnailUrl":"https:\/\/www.abiogen.it\/wp-content\/uploads\/2023\/05\/acquisizione-effrx-min-1.jpg","datePublished":"2023-05-23T07:53:14+00:00","dateModified":"2023-10-17T06:50:37+00:00","author":{"@id":"https:\/\/www.abiogen.it\/en\/#\/schema\/person\/fae38c3588baf3857a429510cbd3d7e5"},"breadcrumb":{"@id":"https:\/\/www.abiogen.it\/en\/acquisition-of-effrx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.abiogen.it\/en\/acquisition-of-effrx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.abiogen.it\/en\/acquisition-of-effrx\/#primaryimage","url":"https:\/\/www.abiogen.it\/wp-content\/uploads\/2023\/05\/acquisizione-effrx-min-1.jpg","contentUrl":"https:\/\/www.abiogen.it\/wp-content\/uploads\/2023\/05\/acquisizione-effrx-min-1.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/www.abiogen.it\/en\/acquisition-of-effrx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.abiogen.it\/en\/"},{"@type":"ListItem","position":2,"name":"Abiogen Pharma completes the acquisition of Effrx"}]},{"@type":"WebSite","@id":"https:\/\/www.abiogen.it\/en\/#website","url":"https:\/\/www.abiogen.it\/en\/","name":"Abiogen","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.abiogen.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.abiogen.it\/en\/#\/schema\/person\/fae38c3588baf3857a429510cbd3d7e5","name":"abnchief","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.abiogen.it\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3cdcc6c7e91f70b1272cb8c09c6f45790581a7a4af465d760eb5ecddb3bdc016?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3cdcc6c7e91f70b1272cb8c09c6f45790581a7a4af465d760eb5ecddb3bdc016?s=96&d=mm&r=g","caption":"abnchief"},"sameAs":["https:\/\/abiogen.tesecom.net"]}]}},"_links":{"self":[{"href":"https:\/\/www.abiogen.it\/en\/wp-json\/wp\/v2\/posts\/5073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abiogen.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abiogen.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abiogen.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abiogen.it\/en\/wp-json\/wp\/v2\/comments?post=5073"}],"version-history":[{"count":3,"href":"https:\/\/www.abiogen.it\/en\/wp-json\/wp\/v2\/posts\/5073\/revisions"}],"predecessor-version":[{"id":5426,"href":"https:\/\/www.abiogen.it\/en\/wp-json\/wp\/v2\/posts\/5073\/revisions\/5426"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.abiogen.it\/en\/wp-json\/wp\/v2\/media\/4641"}],"wp:attachment":[{"href":"https:\/\/www.abiogen.it\/en\/wp-json\/wp\/v2\/media?parent=5073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abiogen.it\/en\/wp-json\/wp\/v2\/categories?post=5073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abiogen.it\/en\/wp-json\/wp\/v2\/tags?post=5073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}